The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Open accessAbstract
Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationTrapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3181 · Cited by 1,469
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Self-citationMcCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Self-citationPromoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226
Role of poly(ADP-ribose) formation in DNA repair
Satoh, M. S., & Lindahl, T. (1992) · Nature · doi:10.1038/356356a0 · Cited by 1,174
(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,121
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Self-citationRequirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,056
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,051
Self-citationResistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Masson, M., Niedergang, C., Schreiber, V., Muller, S., Menissier-de Murcia, J., & de Murcia, G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3563 · Cited by 910
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 903
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.017 · Cited by 836
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Wang, M., Wu, W., Wu, W., Rosidi, B., Zhang, L., Wang, H., & Iliakis, G. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl840 · Cited by 820
Abkevich, V, Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith-McCune, K., Broaddus, R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 815
Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD+ into a nuclear signal
Kim, M. Y., Zhang, T., & Kraus, W. L. (2005) · Genes & Development · doi:10.1101/gad.1331805 · Cited by 802
Poly(ADP-ribose) polymerase: a molecular nick-sensor
de Murcia, G., & de Murcia, J. M. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90280-1 · Cited by 797
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.
Wang, Z. Q., Auer, B., Stingl, L., Berghammer, H., Haidacher, D., Schweiger, M., & Wagner, E. F. (1995) · Genes & Development · doi:10.1101/gad.9.5.509 · Cited by 774
PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase
Amé, J.-C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T., Murcia, J. M.-D., & de Murcia, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17860 · Cited by 745
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
Luo, X., & Kraus, W. L. (2012) · Genes & Development · doi:10.1101/gad.183509.111 · Cited by 725
Schreiber, V., Amé, J.-C., Dollé, P., Schultz, I., Rinaldi, B., Fraulob, V., Ménissier-de Murcia, J., & de Murcia, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202390200 · Cited by 705
Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going?
Hassa, P. O., Haenni, S. S., Elser, M., & Hottiger, M. O. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00040-05 · Cited by 682
Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Langelier, M.-F., Planck, J. L., Roy, S., & Pascal, J. M. (2012) · Science · doi:10.1126/science.1216338 · Cited by 665
Popova, T., Manié, E., Rieunier, G., Caux-Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal-Zafrani, B., Bollet, M., Longy, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1470 · Cited by 665
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 661
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654
Alkylating DNA damage stimulates a regulated form of necrotic cell death
Zong, W.-X., Ditsworth, D., Bauer, D. E., Wang, Z.-Q., & Thompson, C. B. (2004) · Genes & Development · doi:10.1101/gad.1199904 · Cited by 618
PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites
Haince, J.-F., McDonald, D., Rodrigue, A., Déry, U., Masson, J.-Y., Hendzel, M. J., & Poirier, G. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706734200 · Cited by 608
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 602
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Hassa, P. (2008) · Frontiers in Bioscience · doi:10.2741/2909 · Cited by 584
Norquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Self-citationGonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Self-citationLoss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 514
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
Benjamin, R. C., & Gill, D. M. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70491-8 · Cited by 487
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0336 · Cited by 465
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Wahlberg, E., Karlberg, T., Kouznetsova, E., Markova, N., Macchiarulo, A., Thorsell, A.-G., Pol, E., Frostell, Å., Ekblad, T., Öncü, D., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2121 · Cited by 457
Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance
Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457
Self-citationMechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 449
Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins
Ahel, I., Ahel, D., Matsusaka, T., Clark, A. J., Pines, J., Boulton, S. J., & West, S. C. (2008) · Nature · doi:10.1038/nature06420 · Cited by 429
Poly(ADP-Ribose) Regulates Stress Responses and MicroRNA Activity in the Cytoplasm
Leung, A. K. L., Vyas, S., Rood, J. E., Bhutkar, A., Sharp, P. A., & Chang, P. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.015 · Cited by 429
Gagné, J.-P., Isabelle, M., Lo, K. S., Bourassa, S., Hendzel, M. J., Dawson, V. L., Dawson, T. M., & Poirier, G. G. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn771 · Cited by 414
ADP-ribosylation of proteins. Enzymology and biological significance.
Althaus, F. R., & Richter, C. (1987) · PubMed · Cited by 371
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Poly(ADP-ribose) levels in carcinogen-treated cells
Juarez-Salinas, H., Sims, J. L., & Jacobson, M. K. (1979) · Nature · doi:10.1038/282740a0 · Cited by 348
DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines
Trucco, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.11.2644 · Cited by 348
Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
Ying, S., Hamdy, F. C., & Helleday, T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3417 · Cited by 346
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
Physiology and pathophysiology of poly(ADP‐ribosyl)ation *
Bürkle, A. (2001) · BioEssays · doi:10.1002/bies.1115 · Cited by 335
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Involvement of poly(ADP-ribose) polymerase in base excision repair
Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., Rubia, G. D. L., Oliver, J., Rolli, V., Ménissier-de Murcia, J., & de Murcia, G. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80040-6 · Cited by 327
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Rulten, S. L., Fisher, A. E. O., Robert, I., Zuma, M. C., Rouleau, M., Ju, L., Poirier, G., Reina-San-Martin, B., & Caldecott, K. W. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.006 · Cited by 326
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Li, M., & Yu, X. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.025 · Cited by 321
The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
Bai, P., & Cantó, C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.016 · Cited by 312
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
Schultz, N. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg703 · Cited by 301
Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y.-C., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290
Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 290
Boehler, C., Gauthier, L. R., Mortusewicz, O., Biard, D. S., Saliou, J.-M., Bresson, A., Sanglier-Cianferani, S., Smith, S., Schreiber, V., Boussin, F., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016574108 · Cited by 277
Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells
Hochegger, H., Dejsuphong, D., Fukushima, T., Morrison, C., Sonoda, E., Schreiber, V., Zhao, G. Y., Saberi, A., Masutani, M., Adachi, N., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601015 · Cited by 276
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 265
Self-citationHaince, J.-F., Kozlov, S., Dawson, V. L., Dawson, T. M., Hendzel, M. J., Lavin, M. F., & Poirier, G. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608406200 · Cited by 261
Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Dedes, K. J., Wetterskog, D., Mendes-Pereira, A. M., Natrajan, R., Lambros, M. B., Geyer, F. C., Vatcheva, R., Savage, K., Mackay, A., Lord, C. J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001538 · Cited by 255
O'Shaughnessy, J., Schwartzberg, L. S., Danso, M. A., Rugo, H. S., Miller, K., Yardley, D. A., Carlson, R. W., Finn, R. S., Charpentier, E., Freese, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.1007 · Cited by 245
Molinete, M., Vermeulen, W., Bürkle, A., Ménissier-de Murcia, J., Küpper, J. H., Hoeijmakers, J. H., & de Murcia, G. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05859.x · Cited by 244
Yang, Y.-G., Cortes, U., Patnaik, S., Jasin, M., & Wang, Z.-Q. (2004) · Oncogene · doi:10.1038/sj.onc.1207491 · Cited by 242
Synthetic Lethality — A New Direction in Cancer-Drug Development
Iglehart, J. D., & Silver, D. P. (2009) · New England Journal of Medicine · doi:10.1056/nejme0903044 · Cited by 232
Mendoza-Alvarez, H., & Alvarez-Gonzalez, R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41568-2 · Cited by 227
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination–Defective Cells
Gottipati, P., Vischioni, B., Schultz, N., Solomons, J., Bryant, H. E., Djureinovic, T., Issaeva, N., Sleeth, K., Sharma, R. A., & Helleday, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4716 · Cited by 227
PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
Langelier, M.-F., & Pascal, J. M. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.01.003 · Cited by 215
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212
Self-citationHegan, D. C., Lu, Y., Stachelek, G. C., Crosby, M. E., Bindra, R. S., & Glazer, P. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904783107 · Cited by 209
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Yap, T. A., Sandhu, S. K., Carden, C. P., & de Bono, J. S. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20095 · Cited by 208
Robert, I., Dantzer, F., & Reina-San-Martin, B. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082468 · Cited by 203
ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
Huntoon, C. J., Flatten, K. S., Wahner Hendrickson, A. E., Huehls, A. M., Sutor, S. L., Kaufmann, S. H., & Karnitz, L. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0110 · Cited by 202
Self-citationKummar, S., Ji, J., Morgan, R., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D., Kiesel, B., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 199
XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks
Horton, J. K., Watson, M., Stefanick, D. F., Shaughnessy, D. T., Taylor, J. A., & Wilson, S. H. (2008) · Cell Research · doi:10.1038/cr.2008.7 · Cited by 198
Poly(ADP-ribose) Polymerase (PARP-1) in Homologous Recombination and as a Target for Cancer Therapy
Helleday, T., Bryant, H. E., & Schultz, N. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2031 · Cited by 184
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L., Zujewski, J. A., Yu, M., Gordon, N., Ji, J., Sissung, T. M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 184
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
Lord, C. J., McDonald, S., Swift, S., Turner, N. C., & Ashworth, A. (2008) · DNA Repair · doi:10.1016/j.dnarep.2008.08.014 · Cited by 178
PARPs and the DNA damage response
Sousa, F. G., Matuo, R., Soares, D. G., Escargueil, A. E., Henriques, J. A. P., Larsen, A. K., & Saffi, J. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs132 · Cited by 177
Liu, X., Shi, Y., Maag, D. X., Palma, J. P., Patterson, M. J., Ellis, P. A., Surber, B. W., Ready, D. B., Soni, N. B., Ladror, U. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1973 · Cited by 174
Histone shuttling by poly ADP-ribosylation
Althaus, F. R., Höfferer, L., Kleczkowska, H. E., Malanga, M., Naegeli, H., Panzeter, P. L., & Realini, C. A. (1994) · ADP-Ribosylation: Metabolic Effects and Regulatory Functions · doi:10.1007/978-1-4615-2614-8_7 · Cited by 172
Bonicalzi, M.-È., Haince, J.-F., Droit, A., & Poirier, G. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4505-1 · Cited by 171
Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 167
Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress
Gagné, J.-P., Pic, É., Isabelle, M., Krietsch, J., Éthier, C., Paquet, É., Kelly, I., Boutin, M., Moon, K.-M., Foster, L. J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks486 · Cited by 165
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Wang, Z. C., Birkbak, N. J., Culhane, A. C., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K. E., Piao, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0857 · Cited by 160
Histone shuttling by poly(ADP-ribosylation).
Realini, C. A., & Althaus, F. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37040-1 · Cited by 160
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 158
Ang, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 141
Min, W., Bruhn, C., Grigaravičius, P., Zhou, Z., Li, F., Krüger, A., Siddeek, B., Greulich, K., Popp, O., Meisezahl, C., et al. (2013) · Nature Communications · doi:10.1038/ncomms3993 · Cited by 141
Williamson, C. T., Kubota, E., Hamill, J. D., Klimowicz, A. C., Ye, R., Muzik, H., Dean, M. L., Tu, L., Gilley, D. P., Magliocco, A. M., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200229 · Cited by 139
Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing
Malanga, M., & Althaus, F. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300437200 · Cited by 135
PTIP associates with Artemis to dictate DNA repair pathway choice
Wang, J., Asaithamby, A., Löbrich, M., Li, Y., Chen, D. J., Chen, J., & Gong, Z. (2014) · Genes & Development · doi:10.1101/gad.252478.114 · Cited by 134
Lorenzo, S. B. D., Patel, A. G., Hurley, R. M., & Kaufmann, S. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00228 · Cited by 129
Self-citationReview: Modulation of chromatin structure by poly(ADP-ribosyl)ation
de MURCIA, G., Huletsky, A., & Poirier, G. G. (1988) · Biochemistry and Cell Biology · doi:10.1139/o88-072 · Cited by 128
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Forster, M. D., Dedes, K. J., Sandhu, S. K., Frentzas, S., Kristeleit, R. S., Ashworth, A., Poole, C. J., Weigelt, B., Kaye, S. B., & Molife, L. R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.42 · Cited by 128
The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination
Murai, J., Yang, K., Dejsuphong, D., Hirota, K., Takeda, S., & D’Andrea, A. D. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05058-11 · Cited by 128
Nowsheen, S., Cooper, T. S., Stanley, J. A., & Yang, E. S.-H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046614 · Cited by 122
Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme
Sügimura, T., Fujimura, S., Hasegawa, S., & Kawamura, Y. (1967) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(67)90507-2 · Cited by 120
Soni, A., Siemann, M., Grabos, M., Murmann-Konda, T., Pantelias, G. E., & Iliakis, G. E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku298 · Cited by 117
O'Sullivan, C. C., Moon, D. H., Kohn, E. C., & Lee, J. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00042 · Cited by 116
Patel, A. G., Flatten, K. S., Schneider, P. A., Dai, N. T., McDonald, J. S., Poirier, G. G., & Kaufmann, S. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.296475 · Cited by 111
Self-citationSwisher, E. M., Gonzalez, R. M., Taniguchi, T., Garcia, R. L., Walsh, T., Goff, B. A., & Welcsh, P. L. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-48 · Cited by 107
Self-citationPoly(ADP-ribose) polymerases: managing genome stability
Meyer‐Ficca, M. L., Meyer, R. G., Jacobson, E. L., & Jacobson, M. K. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.09.011 · Cited by 106
Liu, X., Han, E. K.-H., Anderson, M. G., Shi, Y., Semizarov, D., Wang, G., McGonigal, T. P., Roberts, L., Lasko, L. M., Palma, J. P., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0299 · Cited by 102
Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential
Min, W., & Wang, Z.-Q. (2009) · Frontiers in bioscience · doi:10.2741/3329 · Cited by 101
The role of poly(ADP-ribosyl)ation in epigenetic events
Quénet, D., Ramy, R. E., Schreiber, V., & Dantzer, F. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.023 · Cited by 100
Hussain, M., Carducci, M. A., Slovin, S. F., Cetnar, J. P., Qian, J. X., McKeegan, E. M., Refici-Buhr, M., Chyla, B., Shepherd, S. P., Giranda, V. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0099-0 · Cited by 98
To, C., Kim, E., Royce, D. B., Williams, C. R., Collins, R. M., Risingsong, R., Sporn, M. B., & Liby, K. T. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0047 · Cited by 87
Zhang, F., Chen, Y., Mo, L., & Yu, X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318367111 · Cited by 71
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
Reinbolt, R. E., & Hays, J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00237 · Cited by 71
Paddock, M. N., Bauman, A. T., Higdon, R., Kolker, E., Takeda, S., & Scharenberg, A. M. (2011) · DNA repair · doi:10.1016/j.dnarep.2010.12.005 · Cited by 68
Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide
Mendeleyev, J., Kirsten, E., Hakam, A., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00189-7 · Cited by 64
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different
Burgess, M. A., & Puhalla, S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00019 · Cited by 61
Huehls, A. M., Wagner, J. M., Huntoon, C. J., Geng, L., Erlichman, C., Patel, A. G., Kaufmann, S. H., & Karnitz, L. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0814 · Cited by 49
Self-citationGeng, L., Huehls, A. M., Wagner, J. M., Huntoon, C. J., & Karnitz, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028862 · Cited by 40
Hassler, M., & Ladurner, A. G. (2012) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2012.08.005 · Cited by 30
Domchek, S. M., Mitchell, G., Lindeman, G. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8134 · Cited by 23
Swisher, E., Brenton, J. D., Kaufmann, S., Oza, A. M., Coleman, R. L., O’Malley, D. M., Konecny, G. E., Ma, L., Harrell, M. I., Visscher, D. W., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70341-7 · Cited by 10
Self-citationHaluska, P., Timms, K., AlHilli, M. M., Wang, Y., Hartman, A., Jones, J. T., Gutin, A., Sangale, Z., Neff, C. D., Lynchbury, J., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70340-5 · Cited by 7
Characterization of ovarian cancer long-term responders on olaparib.
Lheureux, S., Ledermann, J. A., Kaye, S. B., Gourley, C., Friedlander, M. L., Bowtell, D. D. L., Grève, J. D., DeFazio, A., Shapira‐Frommer, R., Bono, J. S. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5534 · Cited by 5
Self-citation
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Self-citationMatulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Self-citation
Metadata
- Authors
- Scott, C. L., Swisher, E. M., & Kaufmann, S. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-04-20
- Volume
- 33
- Issue
- 12
- Pages
- 1397-1406
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2045153367
- Cited by
- 355
- References
- 153
- FWCI
- 21.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.